Literature DB >> 25144596

Precocious puberty.

E Kirk Neely1, Stephanie S Crossen.   

Abstract

PURPOSE OF REVIEW: Precocious puberty continues to elicit great interest and concern among medical practitioners, as well as the public. RECENT
FINDINGS: Studies have elucidated neural regulation of puberty by kisspeptin, neurokinin B, and other factors. Cohort studies from the North America and Europe suggest that the age of thelarche may be earlier than determined 2 decades ago, and menarche may be slightly earlier, but the causes are unclear. Long-term outcomes of gonadotropin-releasing hormone analog therapy demonstrate increases in final height in the youngest treated patients, with no apparent adverse bone or reproductive consequences.
SUMMARY: Although the appropriate threshold age of onset of central puberty remains uncertain, gonadotropin-releasing hormone analog therapy is well tolerated and effective in suppressing luteinizing hormone pulses and ovarian activity.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25144596     DOI: 10.1097/GCO.0000000000000099

Source DB:  PubMed          Journal:  Curr Opin Obstet Gynecol        ISSN: 1040-872X            Impact factor:   1.927


  10 in total

1.  NF-κB-vimentin is involved in steroidogenesis stimulated by di-n-butyl phthalate in prepubertal female rats.

Authors:  Chang Zhang; Pan Gong; Yan Ye; Lulu Zhang; Minjian Chen; Yanhui Hu; Aihua Gu; Shanshan Chen; Yubang Wang
Journal:  Toxicol Res (Camb)       Date:  2018-04-18       Impact factor: 3.524

2.  Sex Differences in the Developmental Neuroscience of Adolescent Substance Use Risk.

Authors:  Mary M Heitzeg; Jillian E Hardee; Adriene M Beltz
Journal:  Curr Opin Behav Sci       Date:  2018-02-20

3.  Unusual side effect from a luteinizing hormone-releasing hormone agonist, leuprorelin, in the treatment of prostate cancer: a case report.

Authors:  John I-Chiang Chang; Joseph Bucci
Journal:  J Med Case Rep       Date:  2016-11-11

Review 4.  Tall Stature: A Challenge for Clinicians.

Authors:  Beatriz Corredor; Mehul Dattani; Chiara Gertosio; Mauro Bozzola
Journal:  Curr Pediatr Rev       Date:  2019

5.  Acupuncture Improving Early Sexual Development of Girls with Peripheral Precocious Puberty: A Prospective Cohort Study.

Authors:  Lili Liu; Naijun Wan; Huihui Sun
Journal:  Evid Based Complement Alternat Med       Date:  2020-04-10       Impact factor: 2.629

6.  Effects of estrogen inhibition formula herbal mixture for danazol-induced precocious puberty in female rats: an experimental study with network pharmacology.

Authors:  Seung Chan Park; Tuy An Trinh; Won-Yung Lee; Ji Yun Baek; Seungyong Lee; Kyuhee Choi; Jaewon Ha; Chang-Eop Kim; Ki Sung Kang; Hye Lim Lee
Journal:  Integr Med Res       Date:  2020-12-16

7.  Preventive Effect of Anemarrhenae rhizome and Phellodendri cortex on Danazol-Induced in Precocious Puberty in Female Rats and Network Pharmacological Analysis of Active Compounds.

Authors:  Kyeong Ri Kim; Tuy An Trinh; Ji Yun Baek; Dahae Lee; Sehun Lim; Jonghyup Kim; Won-Yung Lee; Chang-Eop Kim; Ki Sung Kang; Hye Lim Lee
Journal:  Plants (Basel)       Date:  2021-12-22

Review 8.  Association of PAEs with Precocious Puberty in Children: A Systematic Review and Meta-Analysis.

Authors:  Yi Wen; Shu-Dan Liu; Xun Lei; Yu-Shuang Ling; Yan Luo; Qin Liu
Journal:  Int J Environ Res Public Health       Date:  2015-12-01       Impact factor: 3.390

9.  Improved final predicted height with the injection of leuprolide in children with earlier puberty: A retrospective cohort study.

Authors:  Yi-Chun Lin; Chih-Ying Lin; Siew-Yin Chee; Hung-Rong Yen; Fuu-Jen Tsai; Chiu-Ying Chen; Chung-Hsing Wang
Journal:  PLoS One       Date:  2017-10-03       Impact factor: 3.240

10.  Preventive Effect and Safety of a Follicle Stimulating Hormone Inhibitory Formulation Containing a Mixture of Coicis Semen and Artemisia capillaris for Precocious Puberty: A Preliminary Experimental Study Using Female Rats.

Authors:  Tuy An Trinh; Seung Chan Park; Jihong Oh; Chang-Eop Kim; Ki Sung Kang; Hwa Seung Yoo; Hye Lim Lee
Journal:  Evid Based Complement Alternat Med       Date:  2017-11-20       Impact factor: 2.629

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.